Skip to main content
Premium Trial:

Request an Annual Quote

Quantapore Developing Nanopore Sequencer for Low-Cost Genome Sequencing

Premium

This article was originally published Jan. 23.

Quantapore, a new Silicon Valley company, is working on a nanopore sequencing technology to analyze a human genome in less than one day at low cost.

According to the firm's website, it is developing "a novel, massively parallel sequencer, which will allow rapid, affordable and accurate sequencing of entire genomes."

The proprietary nanopore technology "will eliminate the bottlenecks associated with today's sequencing methods, namely laborious sample preparation, short read length, high cost, and limited throughput," the company said.

Quantapore, based in Menlo Park, Calif., was founded in 2009 by a group of scientists "with various backgrounds" (see Paired Ends, this issue) and raised $700,000 in seed financing in 2010.

Martin Huber, the firm's CEO and a co-founder, invented the nanopore sequencing technology, according to the website, and has previously worked for biotechnology startups in Europe and the US.

Michael Chen, the company's director of engineering, is a visiting scholar at Stanford University's Department of Electrical Engineering.

Huber told In Sequence this week that the company is not yet ready to reveal information about its sequencing technology because it is getting ready for a new financing round.

Quantapore joins a number of companies that are betting on nanopore sequencing, including Oxford Nanopore Technologies and Genia.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.